Muscular atrophy inhibitor
A nutritional approach using coriander, cardamom, long pepper, or cinnamon inhibits muscle atrophy by suppressing MuRF1 and Atrogin-1 expression, addressing the challenge of sarcopenia in elderly individuals.
Patent Information
- Application Number
- JP2024162005
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Elderly individuals face challenges in preventing and improving sarcopenia due to the physical demands of high-intensity exercise, necessitating an easy-to-implement nutritional approach.
A muscle atrophy inhibitor containing crushed or extracted forms of coriander, cardamom, long pepper, or cinnamon, which suppresses the expression of MuRF1 and/or Atrogin-1 genes to inhibit muscle loss.
The inhibitor effectively suppresses skeletal muscle atrophy and prevents or improves sarcopenia by reducing the expression of MuRF1 and Atrogin-1, key genes associated with muscle loss.
Smart Images

Figure 2024166389000001 
Figure 2024166389000002 
Figure 2024166389000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a muscle atrophy inhibitor. [Background technology]
[0002] Sarcopenia is a syndrome that is accompanied by a decrease in skeletal muscle mass and strength due to aging. It has been confirmed that high-intensity training is effective in preventing and improving sarcopenia. However, for elderly people, actively engaging in high-intensity exercise places a large physical burden. For this reason, an easily implemented nutritional approach is desired to prevent and improve sarcopenia. For example, as ingredients that have the effect of improving muscle function, a muscle atrophy inhibitor containing proanthocyanidin as the active ingredient (Patent Document 1), a muscle fiber type transition inhibitor that contains fruit-derived polyphenols as an active ingredient and inhibits the transition of muscle fiber types during disuse muscle atrophy (Patent Document 2), and a muscle function decline inhibitor that contains catechins as active ingredients (Patent Document 3) have been reported. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] JP 2002-338464 A [Patent Document 2] JP 2006-328031 A [Patent Document 3] JP 2008-13473 A Summary of the Invention [Problem to be solved by the invention]
[0004] MuRF1 and Atogin-1 have been reported as genes involved in muscle loss. The object of the present invention is to provide a muscle atrophy inhibitor that can suppress the expression of MuRF1 or Atogin-1 and improve (prevent or treat) sarcopenia. [Means for solving the problem]
[0005] The present inventors conducted extensive research into muscle atrophy inhibitors that can improve (prevent or treat) sarcopenia, and surprisingly discovered that coriander, cardamom, long pepper, and cinnamon inhibit MuRF1 and Atogin-1, which are involved in muscle loss. The present invention is based on these findings. Thus, the present invention provides [1] A muscle atrophy inhibitor comprising, as an active ingredient, at least one crushed or extracted material selected from the group consisting of coriander, cardamom, long pepper, and cinnamon; [2] The muscle atrophy inhibitor according to [1], which suppresses the expression of MuRF1 and / or Atoragin-1. [3] A food composition for inhibiting muscle atrophy, comprising the muscle atrophy inhibitor according to [1] or [2], and [4] A method for inhibiting muscle atrophy (excluding medical procedures for humans), comprising a step of having a subject ingest an effective amount of the muscle atrophy inhibitor according to [1] or [2] or the food composition for inhibiting muscle atrophy according to [3]; Regarding. Effect of the Invention
[0006] The muscle atrophy inhibitor of the present invention can inhibit skeletal muscle atrophy and prevent or ameliorate sarcopenia. [Brief description of the drawings]
[0007] [Figure 1] 1 is a graph showing the effect of the distilled water extract on the expression of the MuRF1 gene. [Diagram 2] 1 is a graph showing the effect of the distilled water extract on the expression of Antrogin-1 gene. [Diagram 3] 1 is a graph showing the effect of the hot water extract on the expression of the MuRF1 gene. [Figure 4] 1 is a graph showing the effect of the hot water extract on the expression of Antrogin-1 gene. [Diagram 5]1 is a graph showing the effect of an ethanol extract on the expression of the MuRF1 gene. [Figure 6] 1 is a graph showing the effect of an ethanol extract on the expression of Antrogin-1 gene. [Figure 7] 1 is a graph showing the effect of a hexane extract on the expression of Antrogin-1 gene. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] Muscle atrophy inhibitor The muscle atrophy inhibitor of the present invention contains at least one crushed or extracted plant selected from the group consisting of coriander, cardamom, long pepper, and cinnamon as an active ingredient. The muscle atrophy inhibitor of the present invention preferably inhibits muscle atrophy by inhibiting the expression of MuRF1 and / or Atrogin-1.
[0009] Sarcopenia Sarcopenia is a decline in muscle strength and physical function caused by a decrease in muscle mass due to aging, disease, lack of exercise, malnutrition, etc. Sarcopenia can be prevented and improved by moderate exercise. However, when elderly people are hospitalized for a long time due to a fracture or other condition, their muscle mass decreases, they are unable to exercise, and they may fall into a vicious cycle in which sarcopenia progresses. As used herein, improvement of sarcopenia includes prevention or treatment.
[0010] (coriander) Coriander used as an active ingredient of the muscle atrophy inhibitor of the present invention is a kind of parsley family and is used as a spice. As a spice, the whole plant is used, the fruit or seed part is called coriander seed, and the leaves or stem part is called coriander leaf or coriander. The coriander of the present invention may be in any form, such as in the state as harvested, or in the state of powder or paste pulverization. The part used is not particularly limited, and may be a specific part only or a mixture of two or more parts. The preferred part is coriander seed or coriander leaf. Furthermore, the active ingredient of the muscle atrophy inhibitor of the present invention may be in a raw state or in a dried state.
[0011] (cardamom) The cardamom used as the active ingredient of the muscle atrophy inhibitor of the present invention may be green cardamom or black cardamom, and may be fresh or dried. It may be in any form, such as in the state as harvested, or in the state of a pulverized powder or paste. The preferred part is the fruit used as a spice, but other parts or a mixture of the fruit and other parts may also be used. A dried or fresh part may be used as the active ingredient of the muscle atrophy inhibitor of the present invention.
[0012] (Long Pepper) The long pepper used as an active ingredient of the muscle atrophy inhibitor of the present invention is a woody climbing plant of the family Piperaceae, also known as long pepper (piper longum L.). The long pepper of the present invention may be in any form, such as in the state as harvested, or in the state of a pulverized powder or paste. The part used is not particularly limited, and may be a specific part only or a mixture of two or more parts. The preferred part is the fruit used as a spice. Furthermore, the active ingredient of the muscle atrophy inhibitor of the present invention may be in a raw state or a dried state.
[0013] (cinnamon) The cinnamon used as the active ingredient of the muscle atrophy inhibitor of the present invention is a tree of the genus Cinnamomum, and may be Chinese cinnamon, Ceylon cinnamon, Indonesian cinnamon, or Indian cinnamon, and may be in any form, such as in the state as harvested, or in the state of a powder or a paste pulverized product. The part used is not particularly limited, and may be a specific part only or a mixture of two or more parts. The preferred part is the bark used as a spice. Furthermore, the active ingredient of the muscle atrophy inhibitor of the present invention may be in a raw state or in a dried state.
[0014] Shatter In the present invention, the pulverized product may be coriander, cardamom, long pepper, or cinnamon (hereinafter, when coriander, etc. is written, coriander, cardamom, long pepper, and cinnamon are referred to), and may be, for example, in the form of powder, granules, or paste. The pulverized product is preferably a powder. The process for processing into the pulverized product or powder is not particularly limited, but may include a process of pulverizing the plant body by any method commonly used by those skilled in the art using a crushing device or instrument such as a crusher, a mill, a blender, a mixer, and a stone mill. Before pulverization, the plant body may be dried by any method commonly used by those skilled in the art, such as hot air of 100° C. or higher, warm air that does not affect the active ingredient, freeze-drying, etc., or the plant body may be dried to a moisture content of 10% by weight or less, and the dried plant body may be stored for a certain period of time.
[0015] When the coriander, etc. contained in the muscle atrophy inhibitor of the present invention is a pulverized product, it is not limited, but for example, the average longest diameter of the pulverized product of coriander, etc. can be 0.01 to 4 mm, preferably 0.02 to 1 mm, more preferably 0.02 to 0.5 mm. In addition, 90% by weight or more of the pulverized product of coriander, etc. can be used that has a longest diameter of 0.01 to 4 mm, preferably 0.02 to 1 mm, more preferably 0.02 to 0.5 mm. In addition, 90% by weight or more of the pulverized product of coriander, etc. can be used that passes through 4.7 mesh (4 mm), 16 mesh (1 mm), or 30 mesh (0.5 mm) in the JIS test sieve mesh conversion table. When the longest diameter of the pulverized product of coriander, etc. is 1 mm or less, the expression of MuRF1 or Atrogin-1 of the present invention is improved, so it is preferable to use a longest diameter of 4 mm or less. The average longest diameter of coriander or the like can be measured using a known device for measuring particle size.
[0016] 《Extract》 The muscle atrophy inhibitor of the present invention may contain an extract of coriander, etc. The muscle atrophy inhibitor of the present invention may contain both a crushed product of coriander, etc. and an extract. The coriander, etc. used for extracting the active ingredient of the muscle atrophy inhibitor of the present invention may be used as is or may be dried. In addition, it may be processed into a crushed or powdered state so as to improve the extraction efficiency.
[0017] The active ingredients can be extracted by any of the usual methods used to extract ingredients derived from plants, including, but not limited to, steam distillation, solvent extraction, pressing (direct, hot or cold), or supercritical extraction. A combination of these extraction methods, such as pressing followed by solvent extraction, may also be used.
[0018] The extraction solvent used when extracting by the solvent extraction method is not limited as long as the active ingredient can be sufficiently extracted into the extract, but for example, an organic solvent, an aqueous solvent, or a mixture of an organic solvent and an aqueous solvent can be used.
[0019] The extract of coriander, etc. contained in the muscle atrophy inhibitor of the present invention can be extracted with an organic solvent, such as alcohol, acetone, benzene, ester, ethyl acetate, hexane, chloroform, and diethyl ether. The alcohol is not limited as long as the active ingredient can be sufficiently extracted in the extract, and can be, for example, a monohydric alcohol having 1 to 5 carbon atoms, such as methanol, ethanol, propyl alcohol, isopropyl alcohol, and butyl alcohol. Polyhydric alcohols having 2 to 5 carbon atoms, such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, can also be used. Preferred alcohols are monohydric alcohols having 1 to 5 carbon atoms, more preferred alcohols are methanol and ethanol, and most preferred alcohol is ethanol.
[0020] The extract of coriander, etc. contained in the muscle atrophy inhibitor of the present invention can be extracted with an aqueous solvent. The aqueous solvent is not limited as long as it contains water, and for example, water, physiological saline, or a buffer solution can be used. Examples of the buffer solution include phosphate buffer, sodium phosphate buffer, sodium carbonate buffer, citrate buffer, citrate phosphate buffer, acetate buffer, and Tris buffer. The pH of the aqueous solvent is not particularly limited.
[0021] The extract of coriander, etc. contained in the muscle atrophy inhibitor of the present invention can be extracted with a mixture of an organic solvent and an aqueous solvent. The amount of the aqueous solvent contained in the extraction solvent is not limited as long as the active ingredient can be sufficiently extracted into the extract, but it can be, for example, 50% by weight or more, 70% by weight or more, or 90% by weight or more based on the total amount of the extraction solvent.
[0022] When extracts such as coriander contained in the muscle atrophy inhibitor of the present invention are extracted by a solvent extraction method, the extraction temperature is not particularly limited as long as the active ingredients can be sufficiently extracted into the extract, but is preferably -50°C to 100°C, more preferably 0°C to 100°C, and most preferably 5°C to 100°C.
[0023] The extraction time of the extract of coriander, etc. contained in the muscle atrophy inhibitor of the present invention can be appropriately determined depending on the state of coriander, etc., that is, when processed into a raw or dried product, or into a crushed or powdered state. Furthermore, the extraction time can be appropriately determined depending on the extraction conditions, such as the temperature of the extract, or the presence or absence of stirring or shaking. The extraction time is preferably 5 seconds to 1 week, more preferably 5 seconds to 1 day, and most preferably 10 minutes to 12 hours. In addition, when extracting the extract of coriander, etc. contained in the muscle atrophy inhibitor of the present invention by a solvent extraction method, it is preferable to carry out the extraction while stirring or shaking so as to improve the extraction efficiency.
[0024] The pressing method is a method of extracting an extract of coriander by applying physical pressure to coriander, etc. There are direct pressing method performed at room temperature, high-temperature pressing method performed at high temperature, and low-temperature pressing method performed at low temperature. The extract contained in the muscle atrophy inhibitor of the present invention can be extracted by any pressing method.
[0025] The extract contained in the muscle atrophy inhibitor of the present invention can be extracted using supercritical extraction. Supercritical extraction is a method of extracting an extract from a specific plant using a substance in a supercritical state. As a substance in a supercritical state, for example, carbon dioxide has a strong dissolving power and is generally used for decaffeinating coffee or extracting flavorings and pharmaceutical ingredients from natural raw materials such as plants.
[0026] (MuRF1) MuRF1 (Muscle RING-Finger Protein-1) is a RING-type ubiquitin ligase with a molecular weight of 40 kDa that is specifically expressed in skeletal and cardiac muscles. It is known that its expression level increases during muscle atrophy. On the other hand, it has been reported that muscle atrophy does not occur in MuRF1 knockout mice, and it is thought to be a protein related to muscle atrophy.
[0027] (Atorogin-1) Atorogin-1, also called MAFbx-1, is an SCF complex ubiquitin ligase with a molecular weight of 40 kDa. SCF complex ubiquitin ligase uses cullin as a platform protein, and E2 binds to the RING domain of Rbx1 (Roc1), and the F-box protein that binds via Skp1 recognizes and ubiquitinates the substrate protein. It is known that the expression level of Atorogin-1 is also increased during muscle atrophy, while it has been reported that muscle atrophy does not occur in Atorogin-1 knockout mice.
[0028] The ground or extracted coriander, which is an active ingredient in the present invention, can be administered to a subject [animal, preferably a mammal (especially a human)] in an effective amount, either alone or preferably together with a pharmaceutically or veterinarily acceptable usual carrier or diluent. It can also be given to animals other than humans in the form of food or drink as feed.
[0029] The muscle atrophy inhibitor of the present invention may be composed of a ground product or extract of coriander, etc., or may contain a ground product or extract of coriander, etc. When the muscle atrophy inhibitor of the present invention contains a ground product or extract of coriander, etc., it may contain other additives.
[0030] The dosage form of the muscle atrophy inhibitor of the present invention is not particularly limited, and examples include oral preparations such as powders, fine granules, granules, tablets, capsules, suspensions, emulsions, syrups, extracts, or pills, or parenteral preparations.
[0031] The oral preparations can be manufactured in accordance with standard methods using excipients such as gelatin, sodium alginate, starch, corn starch, white sugar, lactose, glucose, mannitol, carboxymethylcellulose, dextrin, polyvinylpyrrolidone, crystalline cellulose, soybean lecithin, sucrose, fatty acid esters, talc, magnesium stearate, polyethylene glycol, magnesium silicate, anhydrous silicic acid, or synthetic aluminum silicate, binders, disintegrants, surfactants, lubricants, flow enhancers, diluents, preservatives, colorants, fragrances, flavorings, stabilizers, moisturizers, preservatives, or antioxidants.
[0032] Examples of parenteral preparations include injections. In preparing injections, in addition to the active ingredient, for example, water-soluble solvents such as physiological saline or Ringer's solution, water-insoluble solvents such as vegetable oils or fatty acid esters, isotonicity agents such as glucose or sodium chloride, solubilizers, stabilizers, preservatives, suspending agents, or emulsifiers may be optionally used.
[0033] The muscle atrophy inhibitor of the present invention may contain, but is not limited to, for example, 0.01 to 500 mg / mL, preferably 0.1 to 400 mg / mL, more preferably 0.5 to 300 mg / mL, even more preferably 1 to 200 mg / mL, even more preferably 2 to 150 mg / mL, and most preferably 1 to 100 mg / mL as a dried product obtained by drying an extract of coriander or the like.
[0034] The dosage of the coriander etc. of the present invention can be determined appropriately, but for example, in terms of a dry product obtained by drying the extract, it can be 1 to 3000 mg / kg body weight / day, preferably 5 to 2000 mg / kg body weight / day, more preferably 10 to 1500 mg / kg body weight / day, even more preferably 15 to 1000 mg / kg body weight / day, even more preferably 20 to 800 mg / kg body weight / day, and most preferably 25 to 400 mg / kg body weight / day.
[0035] Furthermore, when the muscle atrophy inhibitor of the present invention is used, the dosage can be 0.1 to 1000 mg / kg body weight / day, preferably 0.5 to 500 mg / kg body weight / day, more preferably 1 to 250 mg / kg body weight / day, even more preferably 3 to 100 mg / kg body weight / day, even more preferably 5 to 50 mg / kg body weight / day, or most preferably 8 to 30 mg / kg body weight / day, as a dried product (or freeze-dried powder) of the obtained extract.
[0036] Of course, the above administration method is an example, and other administration methods may be used. It is desirable that the administration method, dosage, administration period, administration interval, etc. of the muscle atrophy inhibitor to humans be determined through a controlled clinical trial.
[0037] The muscle atrophy inhibitor of the present invention can be administered to humans, but the subjects of administration may also be animals other than humans, including pets such as dogs, cats, rabbits, hamsters, guinea pigs, and squirrels; livestock such as cows and pigs; laboratory animals such as mice and rats; and animals kept in zoos, etc.
[0038] Food Composition The food composition of the present invention includes the muscle atrophy inhibitor of the present invention. The food composition of the present invention may include a food ingredient. In this specification, the food ingredient includes a finished food or beverage such as curry or beer, a spice that is an ingredient of curry or beer, or miso or sake, which can be eaten as a food or beverage as it is and can also be used as an ingredient of cooking.
[0039] Specific examples of foods include fresh prepared foods such as salads; cooked foods such as croquettes, fried white fish, pizza, and hamburgers; stir-fried foods such as stir-fried vegetables; vegetables such as tomatoes, bell peppers, celery, bitter melon, carrots, potatoes, and asparagus, and cooked foods made from these vegetables; confectioneries such as cookies, bread, biscuits, dry bread, cakes, rice crackers, yokan, puddings, jellies, ice cream, chewing gum, crackers, chips, chocolate, and candy; noodles such as udon, pasta, and soba; fish paste products such as kamaboko, ham, and fish sausage; dairy products such as cheese, cream, and butter; condiments such as miso, soy sauce, sauce, dressing, ketchup, mayonnaise, soup base, noodle soup, curry powder, salt and pepper, sesame salt, mirin, oden base, roux, and seasoning spices; soy foods such as tofu; konjac; and supplements. The food product is preferably a sauce (eg, a base for curry, stew, gratin, or pasta), a roux (eg, for curry or stew), a mixed spice, a seasoning spice, or a supplement.
[0040] Examples of beverages include coffee beverages, cocoa beverages, vegetable juices obtained from the above-mentioned vegetables, fruit juice beverages such as grapefruit juice, orange juice, grape juice, and lemon juice, tea beverages such as green tea, black tea, green tea, and oolong tea, alcoholic beverages such as beer, wine (red wine, white wine, sparkling wine, etc.), sake, plum wine, sparkling wine, whiskey, brandy, shochu, rum, gin, and liqueurs, milk beverages, soy milk beverages, liquid diets, and sports beverages. The beverage is preferably spiced tea (e.g., herbal tea or chai).
[0041] The food composition of the present invention can be, for example, in the form of a powder, granule, solid, liquid, capsule, paste, gel, or tablet.
[0042] If desired, these foods or beverages may contain food additives and food ingredients, such as antioxidants, flavorings, acidulants, colorants, emulsifiers, preservatives, seasonings, sweeteners, spices, pH adjusters, stabilizers, antioxidants, vegetable oils, animal oils, sugars and sugar alcohols, vitamins, organic acids, fruit juice extracts, vegetable extracts, grains, beans, vegetables, meats, seafood, etc., either alone or in combination of two or more. The amounts of these food ingredients and food additives to be added may be appropriately determined within the range that does not impair the object of the present invention.
[0043] These foods or beverages can be subjected to common sterilization treatments, such as heat-pressure sterilization using retort and autoclave, batch sterilization, plate sterilization, electric heating sterilization, microwave heating sterilization, and steam sterilization such as injection and infusion.
[0044] Foods and beverages include functional foods (beverages) and health foods (beverages). In this specification, "health foods (beverages)" refers to foods or beverages that have some effect on health or that can be expected to have an effect, and "functional foods (beverages)" refers to foods or beverages that, among the above-mentioned "health foods (beverages), have been designed and processed to fully express a bioregulatory function (i.e., an immunostimulatory function). Functional foods and health foods can be in the form of granules, solids, liquids, capsules, gels, or tablets.
[0045] The food or beverage includes feed for animals, such as primates, including humans, cows, pigs, sheep, goats, horses, dogs, cats, rabbits, rats, and mice.
[0046] 《Method for suppressing muscle atrophy》 The muscle atrophy suppression method of the present invention includes a step of having a subject ingest an effective amount of the muscle atrophy suppressant or the food composition for suppressing muscle atrophy. However, the muscle atrophy suppression method of the present invention does not include medical treatment for humans. Specifically, it includes the ingestion of the muscle atrophy suppressant in a training gym, a nursing facility, etc., and the ingestion of the food composition for suppressing muscle atrophy. The "muscle atrophy inhibitor" and the "food composition for inhibiting muscle atrophy" in the muscle atrophy inhibition method of the present invention are as described in the respective sections. EXAMPLES
[0047] The present invention will be specifically described below with reference to examples, but the scope of the present invention is not limited thereto.
[0048] Example 1 In this example, distilled water extracts were prepared from coriander seeds (dried fruit part) and cardamom (dried fruit part). 20 g of coriander seeds or cardamom were added to 10 times the amount of distilled water (200 g) and mixed. The mixture was stirred at 4°C for 12 hours using a stirrer. The extract was centrifuged at 3200 rpm for 10 minutes. The supernatant was collected and suction filtered through a filter with a maximum pore size of 20 to 25 μm. The resulting supernatant was freeze-dried to obtain a dried water extract.
[0049] Example 2 In this example, hot water extracts were prepared from cinnamon (dried bark), coriander seeds (dried fruit), and cardamom (dried fruit and seeds). Ten times the amount of distilled water (200 g) was added to 20 g of cinnamon, coriander seeds, or cardamom, and mixed. The mixture was stirred at 95°C for 1 hour using a stirrer. The extract was centrifuged at 3200 rpm for 10 minutes. The supernatant was collected and suction filtered through a filter with a maximum pore size of 20 to 25 μm. The resulting supernatant was freeze-dried to obtain a dried product of the hot water extract.
[0050] Example 3 In this example, ethanol extracts were prepared from long pepper (dried fruit) and cinnamon (dried bark). Long pepper and cinnamon powders were suspended in 100% ethanol to a concentration of 1g / mL, and extracted by shaking twice for 15 minutes. After extraction, the supernatant was collected by centrifugation. The solvent was evaporated to dryness using an evaporator, and the weight of the residue was measured. The residue was then dissolved in a mixed solution of dimethyl sulfoxide (DMSO) and ethanol to a concentration of 200mg / mL to obtain a test sample.
[0051] Example 4 In this example, a hexane extract was prepared from cinnamon (dried bark). Powder of long pepper (dried fruit) was suspended in 100% n-hexane to 200g / mL, and extracted by shaking twice for 15 minutes. After extraction, the supernatant was collected by centrifugation. The solvent was evaporated to dryness using an evaporator, and the weight of the residue was measured. It was then dissolved in dimethyl sulfoxide (DMSO) to 200mg / mL to obtain the test sample.
[0052] Example 5 Using a mouse myoblast cell line, the effects of the spice extracts obtained in Examples 1 to 4 on the expression of MuRF1 and Atrogin-1 were examined. Mouse myoblast cell line C2C12, 2 × 10 4 The cells were seeded in a 12-well plate at 100 cells / mL. After pre-culture in 10% FBS-DMEM for 24 hours, the medium was replaced with 0.5% FBS-DMEM (differentiation induction medium) (the differentiation induction medium was replaced once 48 hours after the start of induction). After differentiation, the medium was replaced with a differentiation induction medium containing each spice extract (final concentration 0.01 mg / mL) and treated for 24 hours, and then replaced with a differentiation induction medium containing each spice extract and dexamethasone (Dex: 1 mM) and treated for 24 hours. The addition of dexamethasone increased the expression of MuRF1 and Atrogin-1 genes, making this a model for muscle atrophy.
[0053] The expression of MuRF1 and Atrogin-1 genes in the recovered cells was measured by real-time RT PCR. The pre-cultured cell supernatant was removed, and the cell surface was washed with PBS(-). 1 mL of Sepasol RAN I Super G (Nacalai Tesque) was added to the cells, and the cells were collected by pipetting. 200 μL of chloroform was then added, and the cells were mixed vigorously by inversion for 2 minutes. After mixing, the cells were centrifuged at 12,000 × g for 15 minutes. After centrifugation, 498 μL of the aqueous layer was collected. An equal volume of propanol was added to the collected aqueous layer, mixed by inversion, and then left to stand on ice for 10 minutes. It was then centrifuged at 12,000×g for 10 minutes. After centrifugation, the supernatant was removed, 75% ethanol was added, mixed by inversion, and centrifuged at 12,000×g for 5 minutes. After centrifugation, the supernatant was removed, the mixture was naturally dried, and then ultrapure water was added and left to stand on ice for 15 minutes. The absorbance of the mRNA solution was measured using a spectrophotometer (BioSpec-nano, SHIMADZU) to determine the concentration of mRNA in the solution. An RNA solution containing 100 ng of RNA was filled up to 13.5 μL in a microtube with sterilized ultrapure water, and 0.5 μL of oligo dT primer was added. The mixture of mRNA and oligo dT primer was heated at 70°C for 5 minutes and then cooled at 4°C. 5 μL of dNTP, 5 μL of 5× reverse transcription reaction buffer, 0.5 μL of RNase inhibitor (Invitrogen), 0.2 μL of reverse transcriptase (Nippon Gene), and 0.3 μL of ultrapure water were added and heated at 42°C for 60 minutes. Then, it was cooled at 4°C. After the reaction was completed, it was diluted 40 times with ultrapure water. 1 μL of cDNA, 1 μL each of MuRF1 or Atrogin-1 forward primer and reverse primer, 3 μL of ultrapure water, and 5 μL of DNA detection solution were added to a PCR 96-well plate, and the reaction was carried out under the conditions of 95°C-1 minute, (95°C-3 seconds, 60°C-30 seconds) x 40 cycles. Analysis was performed using the comparative Ct method. β-actin was used as an endogenous control to correct the expression of the target gene. The device used was StepOne Plus (Life Technologies). The respective primers are as follows. MuRF1 forward primer: 5'-TGAGGTGCCTACTTGCTCCT-3'; SEQ ID NO: 1) MuRF1 reverse primer: 5'-TCACCTGGTGGCTATTCTCC-3'; SEQ ID NO: 2) Atrogin-1 forward primer: 5'-ATGCACACTGGTGCAGAGAG-3'; SEQ ID NO: 3) Atrogin-1 reverse primer: 5'-TGTAAGCACACAGGCAGGTC-3'; SEQ ID NO: 4)
[0054] The distilled water extract and hot water extract of cardamom suppressed the expression of MuRF1 and Atrogin-1 (Figures 1-4). The distilled water extract of coriander seed suppressed the expression of MuRF1 and Atrogin-1 (Figures 1-2), and the hot water extract suppressed the expression of Atrogin-1 (Figure 4). The hot water extract and ethanol extract of cinnamon suppressed the expression of Atrogin-1 (Figures 4 and 6). The ethanol extract of long pepper suppressed the expression of MuRF1 (Figure 5), and the hexane extract suppressed the expression of Atrogin-1 (Figure 7). [Industrial Applicability]
[0055] The muscle atrophy inhibitor of the present invention can suppress the expression of MuRF1 and Atrogin-1, the expression of which is increased during muscle atrophy, and improve the symptoms of sarcopenia.
Claims
1. A muscle atrophy inhibitor comprising as an active ingredient at least one crushed or extracted member selected from the group consisting of coriander, cardamom, long pepper, and cinnamon.
2. The muscle atrophy inhibitor according to claim 1, which suppresses the expression of MuRF1 and / or Atoragin-1.
3. A food composition for inhibiting muscle atrophy, comprising the muscle atrophy inhibitor according to claim 1 or 2.
4. A method for inhibiting muscle atrophy (excluding medical procedures for humans), comprising a step of having a subject ingest an effective amount of the muscle atrophy inhibitor according to claim 1 or 2, or the food composition for inhibiting muscle atrophy according to claim 3.
Citation Information
Patent Citations
Muscle activator
JP2017043617A
Muscular atrophy inhibitor
JP2002338464A
Muscular fiber type shift inhibitor
JP2006328031A
Muscle hypofunction inhibitor
JP2008013473A
